NASDAQ: BGLCBionexus Gene Lab Corp Stock
$2.67-0.06 (-2.2%)
Updated Apr 21, 2025
BGLC Price
$2.67
Fair Value Price
-$0.95
Market Cap
$4.80M
52 Week Low
$2.01
52 Week High
$8.40
P/E
-2.97x
P/B
0.58x
P/S
0.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.51M
Earnings
-$1.60M
Gross Margin
13.6%
Operating Margin
-16.55%
Profit Margin
-16.8%
Debt to Equity
0.25
Operating Cash Flow
-$2M
Beta
47.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BGLC Overview
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BGLC's potential to beat the market
- BGLC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Chemical
Industry Rating
C
BGLC
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.11 | A | |
| $41.52 | B | |
| $9.67 | B |
Be the first to know about important BGLC news, forecast changes, insider trades & much more!
BGLC News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BGLC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BGLC ($2.67) is overvalued by 380.28% relative to our estimate of its Fair Value price of -$0.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BGLC ($2.67) is not significantly undervalued (380.28%) relative to our estimate of its Fair Value price of -$0.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BGLC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BGLC due diligence checks available for Premium users.
Valuation
BGLC fair value
Fair Value of BGLC stock based on Discounted Cash Flow (DCF)
Price
$2.67
Fair Value
-$0.95
Undervalued by
380.28%
BGLC ($2.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BGLC ($2.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BGLC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BGLC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.97x
Industry
26.67x
Market
27.14x
BGLC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
3.07x
BGLC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BGLC's financial health
Profit margin
Revenue
$2.5M
Net Income
-$348.3k
Profit Margin
-13.8%
BGLC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BGLC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.4M
Liabilities
$2.1M
Debt to equity
0.25
BGLC's short-term assets ($7.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGLC's short-term assets ($7.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGLC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BGLC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$69.8k
Investing
$494.2k
Financing
$146.6k
BGLC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BGLC vs Specialty Chemical Stocks
Bionexus Gene Lab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.